2 stories on the wire
VERU
2 filings Chronological · ET
VERU
VERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer
Veru will seek an FDA pre-IND meeting in Q4 2026 after preclinical data showed sabizabulin remains potent in daraxonrasib-resistant pancreatic cancer cells.
4 days ago
PRO
VERU
VERU Pivots Sabizabulin to Pancreatic Cancer After Preclinical Data
Veru will take oral sabizabulin into a planned Phase 2b trial in daraxonrasib-resistant pancreatic cancer and drops its cardiovascular inflammation plan.
4 days ago
PRO
No filings match.Try another ticker or clear the filter.